- Molecular NameMesalazine
- Synonym5-aminosalicylate; 5-aminosalicylic acid; 5-ASA; Mesalamine
- Weight153.137
- Drugbank_IDDB00244
- ACS_NO89-57-6
- Show 3D model
- LogP (experiment)0.89
- LogP (predicted, AB/LogP v2.0)1.41
- pkaN/A
- LogD (pH=7, predicted)-1.81
- Solubility (experiment)0.84 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.91
- LogSw (predicted, AB/LogsW2.0)1.83
- Sw (mg/ml) (predicted, ACD/Labs)0.58
- No.of HBond Donors4
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA83.55
- StatusFDA approved
- Administrationoral, rectal
- PharmacologyAn anti-inflammatory drug used to treat inflammation of the digestive tract ulcerative colitis[1] and mild to moderate Crohn's disease.
- Absorption_value25.0
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding50.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRapidly & extensively metabolised intestinal mucosal wall and the liver
- Half life7 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThere have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.
- LD50 (rat)LD50=2800 mg/kg
- LD50 (mouse)LD50=3370 mg/kg